Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with evidence of vascular disease are at increased risk for subsequent vascular events despite effective use of statins to lower the low-density lipoprotein (LDL) cholesterol level. Niacin lowers the LDL cholesterol level and raises the high-density lipoprotein (HDL) cholesterol level, but its clinical efficacy and safety are uncertain. METHODS: After a prerandomization run-in phase to standardize the background statin-based LDL cholesterol-lowering therapy and to establish participants' ability to take extended-release niacin without clinically significant adverse effects, we randomly assigned 25,673 adults with vascular disease to receive 2 g of extended-release niacin and 40 mg of laropiprant or a matching placebo daily. The primary outcome was the first major vascular event (nonfatal myocardial infarction, death from coronary causes, stroke, or arterial revascularization). RESULTS: During a median follow-up period of 3.9 years, participants who were assigned to extended-release niacin-laropiprant had an LDL cholesterol level that was an average of 10 mg per deciliter (0.25 mmol per liter as measured in the central laboratory) lower and an HDL cholesterol level that was an average of 6 mg per deciliter (0.16 mmol per liter) higher than the levels in those assigned to placebo. Assignment to niacin-laropiprant, as compared with assignment to placebo, had no significant effect on the incidence of major vascular events (13.2% and 13.7% of participants with an event, respectively; rate ratio, 0.96; 95% confidence interval [CI], 0.90 to 1.03; P=0.29). Niacin-laropiprant was associated with an increased incidence of disturbances in diabetes control that were considered to be serious (absolute excess as compared with placebo, 3.7 percentage points; P<0.001) and with an increased incidence of diabetes diagnoses (absolute excess, 1.3 percentage points; P<0.001), as well as increases in serious adverse events associated with the gastrointestinal system (absolute excess, 1.0 percentage point; P<0.001), musculoskeletal system (absolute excess, 0.7 percentage points; P<0.001), skin (absolute excess, 0.3 percentage points; P=0.003), and unexpectedly, infection (absolute excess, 1.4 percentage points; P<0.001) and bleeding (absolute excess, 0.7 percentage points; P<0.001). CONCLUSIONS: Among participants with atherosclerotic vascular disease, the addition of extended-release niacin-laropiprant to statin-based LDL cholesterol-lowering therapy did not significantly reduce the risk of major vascular events but did increase the risk of serious adverse events. (Funded by Merck and others; HPS2-THRIVE ClinicalTrials.gov number, NCT00461630.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the EU, treatment with niacin was stopped after the AIM-HIGH and HPS2-THRIVE trials showed no improvement in MACE and an increased occurrence of undesirable side effects [123, 124].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [124]
In the citing paper
“Nonetheless, these studies also did not prospectively enroll patients with elevated TG levels despite statin therapy,6, 12, 13, 14, 15”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [14]
In the citing paper
“Prior CV outcome studies that administered therapies with TG‐lowering effects (niacin or fenofibrate) on top of statin therapy did not reach their primary endpoints.”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [14]
In the citing paper
“and an increased incidence of new-onset diabetes (absolute excess, 1.3 percentage points; P < 0.001) and disturbances in diabetes management among those with diabetes in the HPS2-THRIVE trial in those on combination therapy (161).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [161]
In the citing paper
“Large clinical trials, including the Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trials, failed to demonstrate a benefit of adding niacin to individuals on appropriate statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [161]
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Prostaglandins and Inflammation
Ricciotti, E., & FitzGerald, G. A. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.207449 · Cited by 3,803
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Clofibrate and Niacin in Coronary Heart Disease
(1975) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1975.03240160024021 · Cited by 1,747
Cited by
Items 301–400 of 1,676
Kalil, R. S., Wang, J., de Boer, I. H., Mathew, R. O., Ix, J. H., Asif, A., Shi, X., & Boden, W. E. (2015) · Kidney International · doi:10.1038/ki.2014.383 · Cited by 68
Supplemental Vitamins and Minerals for Cardiovascular Disease Prevention and Treatment
Inglés, D. P., Rodriguez, J. B. C., & García, H. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-1270-1 · Cited by 79
The Role of Emerging Risk Factors in Cardiovascular Outcomes
Lacey, B., Herrington, W. G., Preiss, D., Lewington, S., & Armitage, J. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0661-2 · Cited by 79
Hegele, R. A., Gidding, S. S., Ginsberg, H. N., McPherson, R., Raal, F. J., Rader, D. J., Robinson, J. G., & Welty, F. K. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.306442 · Cited by 63
Kjeldsen, E. W., Thomassen, J. Q., & Frikke‐Schmidt, R. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.159063 · Cited by 76
Very High High-Density Lipoprotein Cholesterol Levels and Cardiovascular Mortality
Liu, C., Dhindsa, D. S., Almuwaqqat, Z., Sun, Y. V., & Quyyumi, A. A. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.11.041 · Cited by 68
Li, H., Qian, F., Zuo, Y., Yuan, J., Chen, S., Wu, S., & Wang, A. (2022) · Stroke · doi:10.1161/strokeaha.121.034393 · Cited by 74
Do patients benefit from omega-3 fatty acids?
Sherratt, S. C. R., Mason, R. P., Libby, P., Steg, P. G., & Bhatt, D. L. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad188 · Cited by 79
Nontraditional Serum Lipid Variables and Recurrent Stroke Risk
Park, J., Lee, J., & Ovbiagele, B. (2014) · Stroke · doi:10.1161/strokeaha.114.006827 · Cited by 67
“HDL-raising agent (niacin) did not reduce risk of major vascular events in 2 distinct trials.(33,34) These latter results may cast”
ResultHDL Cholesterol Efflux Capacity: Cardiovascular Risk Factor and Potential Therapeutic Target
Bhatt, A. B., & Rohatgi, A. K. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0554-1 · Cited by 73
Maki, K. C., Guyton, J. R., Orringer, C. E., Hamilton-Craig, I., Alexander, D. D., & Davidson, M. H. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2016.03.008 · Cited by 62
LP(a): Structure, Genetics, Associated Cardiovascular Risk, and Emerging Therapeutics
Tasdighi, E., Adhikari, R., Almaadawy, O., Leucker, T. M., & Blaha, M. J. (2023) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-031023-100609 · Cited by 72
Croyal, M., Ouguerram, K., Passard, M., Ferchaud-Roucher, V., Chétiveaux, M., Billon-Crossouard, S., de Gouville, A.-C., Lambert, G., Krempf, M., & Nobécourt, E. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.305835 · Cited by 62
Riaz, H., Khan, S. U., Rahman, H., Shah, N. P., Kaluski, E., Lincoff, A. M., & Nissen, S. E. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487318816495 · Cited by 61
Molecular regulation of plasma lipid levels during systemic inflammation and sepsis
Trinder, M., Boyd, J. H., & Brunham, L. R. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000577 · Cited by 62
HDL: Fact, fiction, or function? HDL cholesterol and cardiovascular risk
Allard‐Ratick, M., Kindya, B., Khambhati, J., Engels, M. C., Sandesara, P. B., Rosenson, R. S., & Sperling, L. S. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319848214 · Cited by 67
Reverri, E. J., Morrissey, B. M., Cross, C. E., & Steinberg, F. M. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.08.005 · Cited by 72
Therapy with cholesteryl ester transfer protein (CETP) inhibitors and diabetes risk
Masson, W., Lobo, M., Siniawski, D., Huerín, M., Molinero, G., Valéro, R., & Nogueira, J. P. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.02.005 · Cited by 61
“not have diabetes at the time of randomization, showed that the niacin-laropiprant treated group had a 32% increased risk of diabetes compared to the placebo group [17].”
BackgroundInvestigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19
Talasaz, A. H., Sadeghipour, P., Aghakouchakzadeh, M., Dreyfus, I., Kakavand, H., Ariannejad, H., Gupta, A., Madhavan, M. V., Tassell, B. W. V., Jiménez, D., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.08.021 · Cited by 65
Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias
Gareri, C., Polimeni, A., Giordano, S., Tammè, L., Curcio, A., & Indolfi, C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11133884 · Cited by 59
Lipoprotein(a) Levels and Recurrent Vascular Events After First Ischemic Stroke
Lange, K. S., Nave, A. H., Liman, T., Grittner, U., Endres, M., & Ebinger, M. (2016) · Stroke · doi:10.1161/strokeaha.116.014436 · Cited by 63
“Тем не менее поскольку по результатам недавних исследований, проведенных совместной группой HPS2THRIVE (Heart Protection Study 2–Treatment of HDL to Reduce the Incidence of Vascular Events), обнаружили, что частота развития неблагоприятных событий превышает снижение сердечно-сосудистого риска [37, 38], применение новы…”
Cholesterol Lowering and Prevention of Stroke: An Overview
Hackam, D. G., & Hegele, R. A. (2019) · Stroke · doi:10.1161/strokeaha.118.023167 · Cited by 72
Alexopoulos, A., Qamar, A., Hutchins, K., Crowley, M. J., Batch, B. C., & Guyton, J. R. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1136-3 · Cited by 75
Kassner, U., Schlabs, T., Rosada, A., & Steinhagen‐Thiessen, E. (2015) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2015.02.039 · Cited by 59
Novel therapeutic targets and emerging treatments for atherosclerotic cardiovascular disease
Zheng, W. C., Chan, W., Dart, A., & Shaw, J. A. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad074 · Cited by 59
The New Dyslipidemia Guidelines: What Is the Debate?
Anderson, T. J., Mancini, G. B. J., Genest, J. J., Grégoire, J. C., Lonn, E., & Hegele, R. A. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.11.007 · Cited by 65
Statin Intolerance: the Clinician’s Perspective
Stulc, T., Ceška, R., & Gotto, A. M. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0552-3 · Cited by 58
New Era of Lipid-Lowering Drugs
Barter, P. J., & Rye, K. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012203 · Cited by 65
Two Decades of Cardiovascular Trials With Primary Surrogate Endpoints: 1990–2011
Bikdeli, B., Punnanithinont, N., Akram, Y., Lee, I., Desai, N. R., Ross, J. S., & Krumholz, H. M. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005285 · Cited by 59
Otvos, J. D., Guyton, J. R., Connelly, M. A., Akapame, S., Bittner, V., Kopecky, S. L., Lacy, M., Marcovina, S. M., Muhlestein, J. B., & Boden, W. E. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.01.002 · Cited by 61
Horimatsu, T., Blomkalns, A. L., Ogbi, M., Moses, M. M., Kim, D. S., Patel, S. Y., Gilreath, N., Reid, L. E., Benson, T. W., Pye, J., et al. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz303 · Cited by 59
“Niacin, when added to statin therapy, failed to reduce atherosclerotic events in the AIM-HIGH and HPS2-THRIVE trials.(44,45) These data cannot be extrapolated to AAA, which is a distinct disease process from atherosclerosis.”
BackgroundWhat do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery?
Cybulska, B., Kłosiewicz−Latoszek, L., Penson, P. E., & Banach, M. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2020.04.004 · Cited by 61
Peterson, B. E., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Juliano, R. A., Jiao, L., Doyle, R. T., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.050276 · Cited by 57
Khera, A. V., Qamar, A., Reilly, M. P., Dunbar, R. L., & Rader, D. J. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.10.018 · Cited by 60
Hypertriglyceridemia and Cardiovascular Diseases: Revisited
Han, S. H., Nicholls, S. J., Sakuma, I., Zhao, D. H., & Koh, K. K. (2016) · Korean Circulation Journal · doi:10.4070/kcj.2016.46.2.135 · Cited by 70
Plant sterol enriched functional food and atherosclerosis
Köhler, J., Teupser, D., Elsässer, A., & Weingärtner, O. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13764 · Cited by 59
Saito, I., Yamagishi, K., Kokubo, Y., Yatsuya, H., Iso, H., Sawada, N., Inoue, M., & Tsugane, S. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.08.032 · Cited by 61
Hypercholesterolaemia – practical information for non-specialists
Soran, H., Adam, S., Mohamad, J. B., Ho, J. H., Schofield, J. D., Kwok, S., Siahmansur, T. J., Liu, Y., Syed, A. A., Dhage, S. S., et al. (2018) · Archives of Medical Science · doi:10.5114/aoms.2018.72238 · Cited by 70
Supplemental Vitamins and Minerals for Cardiovascular Disease Prevention and Treatment
Sunkara, A., & Raizner, A. E. (2019) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-15-3-179 · Cited by 68
Kühnast, S., Fiocco, M. F., van der Hoorn, J. W. A., Princen, H. M. G., & Jukema, J. W. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.089 · Cited by 63
Tehrani, D. M., Zhao, Y., Blaha, M. J., Mora, S., Mackey, R. H., Michos, E. D., Budoff, M. J., Cromwell, W., Otvos, J. D., Rosenblit, P. D., et al. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.03.040 · Cited by 56
“Given this, it should be no surprise that in those with DM, HDL-C may reflect metabolic risk and not add to event prediction and possibly why recent clinical trials that increased HDL-C but had minimal effects on HDL-P(19) failed to show CVD protection.(20,21) Persons with DM carry significant residual risk that inade…”
ResultHigh-Density Lipoprotein Cholesterol and All-Cause and Cause-Specific Mortality Among the Elderly
Li, Z., Lv, Y., Zhong, W.-F., Gao, X., Kraus, V. B., Zou, M., Zhang, X.-R., Li, F.-R., Yuan, J.-Q., Shi, X., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02511 · Cited by 55
Andersson, C., Lyass, A., Larson, M. G., Robins, S. J., & Vasan, R. S. (2015) · Diabetologia · doi:10.1007/s00125-015-3762-x · Cited by 57
“increased risk of diabetes mellitus in randomised controlled trials [1, 2].”
BackgroundToth, P. P., Fazio, S., Wong, N. D., HULL, M. L., & Nichols, G. A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13921 · Cited by 69
Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes
Khavandi, M., Duarte, F., Ginsberg, H. N., & Reyes‐Soffer, G. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0818-1 · Cited by 66
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S. E., Davidson, M., EINHORN, D. F., Garber, J. R., et al. (2015) · Endocrine Practice · doi:10.4158/ep151063.cs · Cited by 55
Niacin for treatment of nonalcoholic fatty liver disease (NAFLD): novel use for an old drug?
Kashyap, M. L., Ganji, S., Nakra, N. K., & Kamanna, V. S. (2019) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2019.10.006 · Cited by 54
Ooi, E. M., Watts, G. F., Chan, D. C., Pang, J., Tenneti, V. S., Hamilton, S. J., McCormick, S. P., Marcovina, S. M., & Barrett, P. H. R. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.306136 · Cited by 54
“including the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride: Impact on Global Health Outcomes (AIM-HIGH) and Heart Protection Study 2-Treament of HDL to Reduce the Incidence of Vascular Events (HPS-2 THRIVE), where niacin is added to aggressive LDL cholesterol–lowering statin thera…”
MethodCombined dyslipidemia in childhood
Kavey, R.-E. W. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.06.008 · Cited by 66
Future perspectives of the pharmacological management of diabetic dyslipidemia
Patti, A. M., Giglio, R. V., Παπάνας, Ν., Rizzo, M., & Rizvi, A. A. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1567328 · Cited by 58
“the risk of major CVD events but substantially increased the risk of serious adverse events and of diabetes in patients with CVD [36].”
BackgroundContemporary Management of Dyslipidemia
Ferraro, R., Leucker, T. M., Martin, S. S., Banach, M., Jones, S. R., & Toth, P. P. (2022) · Drugs · doi:10.1007/s40265-022-01691-6 · Cited by 66
Target Populations for Novel Triglyceride-Lowering Therapies
Nordestgaard, A. T., Tybjærg-Hansen, A., Mansbach, H., Kersten, S., Nordestgaard, B. G., & Rosenson, R. S. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.02.035 · Cited by 54
Andrews, J., Janssan, A., Nguyen, T., Pisaniello, A. D., Scherer, D. J., Kastelein, J. J. P., Merkely, B., Nissen, S. E., Ray, K., Schwartz, G. G., et al. (2017) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2017.01.01 · Cited by 53
“Orally bioavailable drugs that increase HDL-C concentration, including niacin, fibrates, and cholesteryl ester transfer protein (CETP) inhibitors have not been found to provide clinical benefit when added to statins (18-23).”
BackgroundLow-Normal Thyroid Function and Novel Cardiometabolic Biomarkers
van Tienhoven‐Wind, L. J. N., & Dullaart, R. P. F. (2015) · Nutrients · doi:10.3390/nu7021352 · Cited by 55
Human genetics of HDL: Insight into particle metabolism and function
Brunham, L. R., & Hayden, M. R. (2015) · Progress in Lipid Research · doi:10.1016/j.plipres.2015.01.001 · Cited by 53
A review of PCSK9 inhibition and its effects beyond LDL receptors
Dixon, D. L., Trankle, C., Buckley, L., Parod, E., Carbone, S., Van Tassell, B. W., & Abbate, A. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2016.07.004 · Cited by 53
Effects of Diet on 10-Year Atherosclerotic Cardiovascular Disease Risk (from the DASH Trial)
Jeong, S. Y., Wee, C. C., Kovell, L. C., Plante, T. B., Miller, E. R., Appel, L. J., Mukamal, K. J., & Juraschek, S. P. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.10.019 · Cited by 69
Alhomoud, I. S., Talasaz, A. H., Mehta, A., Kelly, M. S., Sisson, E. M., Bucheit, J. D., Brown, R., & Dixon, D. L. (2023) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2851 · Cited by 63
Combination therapy in dyslipidemia: Where are we now?
Catapano, A. L., Farnier, M., Foody, J. M., Toth, P. P., Tomassini, J. E., Brudi, P., & Tershakovec, A. M. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.09.026 · Cited by 55
“[31] HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.”
BackgroundMethodInfluentialNicholls, S. J., Ruotolo, G., Brewer, H. B., Wang, M.-D., Liu, L., Willey, M. B., Deeg, M. A., Krueger, K. A., & Nissen, S. E. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.11.014 · Cited by 53
Triglycerides, Atherosclerosis, and Cardiovascular Outcome Studies: Focus on Omega-3 Fatty Acids
Handelsman, Y., & Shapiro, M. D. (2016) · Endocrine Practice · doi:10.4158/ep161445.ra · Cited by 60
“The Heart Protection Study 2–Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2THRIVE) evaluated extended-release niacin with the antiflushing agent laropiprant as add-on to statin therapy in patients with a history of MI, cerebrovascular disease, peripheral arterial disease, or diabetes with evidence o…”
New Frontiers in Lp(a)-Targeted Therapies
Borrelli, M. J., Youssef, A., Boffa, M. B., & Koschinsky, M. L. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.01.004 · Cited by 57
O’Fee, K., Deych, E., Ciani, O., & Brown, D. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.5726 · Cited by 59
Santos‐Gallego, C. G. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.08.027 · Cited by 54
Antisense Oligonucleotides Targeting Lipoprotein(a)
Langsted, A., & Nordestgaard, B. G. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0792-8 · Cited by 53
Lipoprotein(a) and calcific aortic valve stenosis: A systematic review
Guddeti, R. R., Patil, S., Ahmed, A., Sharma, A., Aboeata, A., Lavie, C. J., & Alla, V. M. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2020.06.002 · Cited by 55
High Density Lipoproteins and Diabetes
Cochran, B. J., Ong, K. L., Manandhar, B., & Rye, K. (2021) · Cells · doi:10.3390/cells10040850 · Cited by 61
LCAT- targeted therapies: Progress, failures and future
Yang, K., Wang, J., Xiang, H., Ding, P., Wu, T., & Ji, G. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112677 · Cited by 56
The Role of High-Density Lipoprotein Cholesterol in 2022
Sirtori, C. R., Corsini, A., & Ruscica, M. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01012-y · Cited by 60
Dysfunctional High-Density Lipoprotein Cholesterol and Coronary Artery Disease: A Narrative Review
Madaudo, C., Bono, G., Ortello, A., Astuti, G., Mingoia, G., Galassi, A. R., & Sucato, V. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14090996 · Cited by 67
“The HPS2-THRIVE study similarly found no additional reduction in CVD risk when niacin–laropiprant therapy was added to statin-treated patients with low LDL, non-HDL levels, and normal HDL levels [58].”
BackgroundInflammation and beyond: new directions and emerging drugs for treating atherosclerosis
Bertrand, M.-J., & Tardif, J. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2017.1269743 · Cited by 59
Time to ditch HDL-C as a measure of HDL function?
Ronsein, G. E., & Heinecke, J. W. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000446 · Cited by 52
“However, two independent clinical trials with niacin added to statin therapy failed to show clinical benefits [6,7].”
Sherratt, S. C. R., & Mason, R. P. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.01.062 · Cited by 51
Chen, J., Li, Y., Zhang, Y., Wang, Y., Zhou, Y., Geng, T., Liu, G., Pan, A., & Liao, Y.-F. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155817 · Cited by 56
High-Density Lipoproteins: Biology, Epidemiology, and Clinical Management
Choi, H. Y., Hafiane, A., Schwertani, A. G., & Genest, J. J. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.09.012 · Cited by 59
Elshazly, M. B., Quispe, R., Michos, E. D., Sniderman, A. D., Toth, P. P., Banach, M., Kulkarni, K. R., Coresh, J., Blumenthal, R. S., Jones, S. R., et al. (2015) · Circulation · doi:10.1161/circulationaha.115.016163 · Cited by 58
High-density lipoproteins (HDL): Novel function and therapeutic applications
Darabi, M., & Kontush, A. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.159058 · Cited by 57
Digoxin reduces atherosclerosis in apolipoprotein E‐deficient mice
Shi, H., Mao, X., Zhong, Y., Liu, Y., Zhao, X., Yu, K., Zhu, R., Wei, Y., Zhu, J., Sun, H., et al. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13453 · Cited by 49
“…triglycerides and LDL cholesterol significantly affect the incidence of major vascular events and the development of atherosclerosis in humans (Heart Protection Study Collaborative, 2002; National Cholesterol Education Program Expert Panel on Detection et al., 2002; Group et al., 2014).”
BackgroundTalayero, B., Wang, L., Furtado, J., Carey, V. J., Bray, G. A., & Sacks, F. M. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m042333 · Cited by 49
Alamir, M. A., Goyfman, M., Chaus, A. M., Dabbous, F., Tamura, L. K., Sandfort, V., Brown, A. S., & Budoff, M. J. (2018) · Journal of Lipids · doi:10.1155/2018/5607349 · Cited by 69
“The association between multivessel coronary artery disease and the cardiovascular risk factors, including dyslipidemia, had been widely studied in patients with documented clinical CVD, using invasive coronary angiography [27, 28].”
BackgroundHypertriglyceridemia: new approaches in management and treatment
Wolska, A., Yang, Z.-H., & Remaley, A. T. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000710 · Cited by 49
Niacin and HDL Cholesterol — Time to Face Facts
Lloyd‐Jones, D. M. (2014) · New England Journal of Medicine · doi:10.1056/nejme1406410 · Cited by 48
Lipids, Lipoproteins, and Cardiovascular Disease: Clinical Pharmacology Now and in the Future
Chait, A., & Eckel, R. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3940 · Cited by 54
Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT
Griffin, S. J., Bethel, M. A., Holman, R. R., Khunti, K., Wareham, N. J., Brierley, G., Davies, M. J., Dymond, A., Eichenberger, R., Evans, P. H., et al. (2018) · Health Technology Assessment · doi:10.3310/hta22180 · Cited by 50
Berman, A. N., & Blankstein, R. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1175-z · Cited by 55
Jain, N., Bhansali, S., Kurpad, A. V., Hawkins, M. A., Sharma, A. D., Kaur, S., Rastogi, A., & Bhansali, A. K. (2019) · Scientific Reports · doi:10.1038/s41598-019-55466-3 · Cited by 56
Lipoprotein signatures of cholesteryl ester transfer protein and HMG-CoA reductase inhibition
Kettunen, J., Holmes, M. V., Allara, E., Anufrieva, O., Ohukainen, P., Oliver-Williams, C., Wang, Q., Tillin, T., Hughes, A. D., Kähönen, M., et al. (2019) · PLOS Biology · doi:10.1371/journal.pbio.3000572 · Cited by 47
Dyslipidemia management update
Chang, Y., & Robidoux, J. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.04.005 · Cited by 55
Kronenberg, F. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_504 · Cited by 59
“…in patients with optimally low levels of LDL-C, and despite favorable effects on HDL-C, triglycerides, and Lp(a), two clinical outcome trials failed to show any incremental clinical benefit on cardiovascular events with niacin when added to simvastatin (Boden et al. 2011; Landray et al. 2014).”
Gao, S., Xu, H., Ma, W., Yuan, J., & Yu, M. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.024366 · Cited by 47
Hovingh, G. K., Rader, D. J., & Hegele, R. A. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000161 · Cited by 54
Cardiovascular Disease Risk Assessment and Prevention
Alagona, P., & Ahmad, T. A. (2015) · Medical Clinics of North America · doi:10.1016/j.mcna.2015.02.003 · Cited by 57
Hypertriglyceridemia: the importance of identifying patients at risk
Kushner, P. A., & Cobble, M. E. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1243005 · Cited by 47
Serum Concentration of HDL Particles Predicts Mortality in Acute Heart Failure Patients
Potočnjak, I., Degoricija, V., Trbušić, M., Pregartner, G., Berghold, A., Marsche, G., & Frank, S. (2017) · Scientific Reports · doi:10.1038/srep46642 · Cited by 46
Zhang, H., Xu, Y., & Xu, Y. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02115-y · Cited by 53
Friedman, E. A., Ogletree, M. L., Haddad, E. V., & Boutaud, O. G. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.05.027 · Cited by 59
“However, this combination was abandoned because it caused more harm than good in a large clinical trial (HPS2-THRIVE) [30].”
Karalis, D. G. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0462-y · Cited by 59
“In the Heart Protection Study 2–Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trial extended-release niacin and laropiprant when added to a statin did not significantly reduce major CV events in patients with atherosclerotic vascular disease, but increased the risk of bleeding, infection, w…”
BackgroundA high-power and fast charging Li-ion battery with outstanding cycle-life
Agostini, M., Brutti, S., Navarra, M. A., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01236-y · Cited by 46
Niacin and heart disease prevention: Engraving its tombstone is a mistake
Superko, H. R., Zhao, X.-Q., Hodis, H. N., & Guyton, J. R. (2017) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2017.08.005 · Cited by 46
Dietary natural products as emerging lipoprotein(a)‐lowering agents
Momtazi‐Borojeni, A. A., Katsiki, N., Pirro, M., Banach, M., Al‐Rasadi, K., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28134 · Cited by 49
“…2012; Mellwig et al., 2015), peripheral artery disease (Gurdasani et al., 2012), cerebrovascular disease (Emerging Risk Factors Collaboration, 2009; Gurdasani et al., 2012), abdominal aortic aneurysm (Kotani et al., 2017), aortic valve calcification and stenosis (Vongpromek et al., 2015), as well…”
Background
Metadata
- Authors
- The HPS2-THRIVE Collaborative Group
- Corresponding author
- The HPS2-THRIVE Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-17
- Volume
- 371
- Issue
- 3
- Pages
- 203-212
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1856460279
- Cited by
- 1,668
- References
- 33
- Citations by year
- 2026: 72 · 2025: 73 · 2024: 107 · 2023: 113 · 2022: 115 · 2021: 119 · 2020: 132 · 2019: 144 · 2018: 149 · 2017: 159 · 2016: 203 · 2015: 204 · 2014: 71
- FWCI
- 210.23
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion, other-oa)
- Funders
- Harbin Medical University
- Second Affiliated Hospital of Harbin Medical University
- Cancer Research UK
- National Institute for Health and Care Research (CDF-2013-06-012)
- British Heart Foundation (RE/08/004)
- Tongji University
- Zhengzhou University
- Qingdao University
- First Affiliated Hospital of Zhengzhou University
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- extended-release niacin, laropiprant, LDL cholesterol lowering, HDL cholesterol, major vascular events, secondary prevention, vascular disease, statin therapy, diabetes management, adverse events, cardiovascular risk reduction, lipid-lowering therapy, coronary artery disease, stroke, myocardial infarction, arterial revascularization, infection risk
- MeSH terms
- Aged, Hypolipidemic Agents, Delayed-Action Preparations, Diabetes Mellitus, Double-Blind Method, Drug Combinations, Female, Follow-Up Studies, Hemorrhage, Humans, Hypercholesterolemia, Indoles, Infections, Cholesterol, LDL, Male, Middle Aged, Musculoskeletal Diseases, Niacin, Risk Factors, Treatment Failure, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.